Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06201663

Romiplostim in Chemotherapy-Induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia Clinical Trial

Official title:
Safety and Efficacy of Romiplostim in Chemotherapy-Induced Thrombocytopenia in Children and Adolescents With Solid Malignancy

Clinical Trial Summary

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

Clinical Trial Description

Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing delays in treatment and dose reduction for subsequent administration of cancer-directed treatment. Romiplostim is a potential agent that can improve platelet counts, allowing the resumption of chemotherapy, decreasing the need for platelet transfusions, and increasing the nadir platelet counts thus improving dose intensity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06201663
Study type Interventional
Source Ain Shams University
Contact
Status Recruiting
Phase Phase 3
Start date December 17, 2023
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969158 - Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma Phase 2
Active, not recruiting NCT03362177 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer Phase 3
Recruiting NCT05554913 - Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Completed NCT05688306 - To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
Completed NCT00283439 - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06099925 - The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies Phase 2
Completed NCT03471078 - Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers Phase 3
Active, not recruiting NCT03976882 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. Phase 3
Recruiting NCT05772546 - Avatrombopag vs. Placebo for CIT in GI Malignancies Phase 2
Not yet recruiting NCT05864014 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. Phase 3
Terminated NCT01345214 - A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia Phase 1
Completed NCT01663441 - A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 Phase 3
Recruiting NCT05236582 - Herombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Not yet recruiting NCT05944211 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia Phase 2
Withdrawn NCT03343847 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. Phase 3
Completed NCT05851027 - Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Not yet recruiting NCT03049774 - A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor N/A
Recruiting NCT03937154 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Phase 3
Recruiting NCT05218226 - Avatrombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Recruiting NCT04600960 - Eltrombopag for Chemotherapy-induced Thrombocytopenia Phase 2